BioXell S.p.A. announces change in management

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Milan, Italy, July 24, 2008 - BioXell S.p.A. (SWX: BXLN) today
announced that Enrico Colli, Chief Medical Officer, has resigned from
the Company for personal reasons in order to pursue a career at a
large pharmaceutical organization. He is expected to leave the
Company at the end of September. Francesco Sinigaglia, Chief
Executive Officer, will take over the responsibility for his function
on an interim basis until a successor is appointed.

"Enrico Colli has contributed significantly to the successful
development of our Company since he joined BioXell in 2002" commented
Francesco Sinigaglia. "I would like to acknowledge the excellent work
Enrico has done in setting up the clinical programs for Elocalcitol,
our lead compound. Today, Elocalcitol has the potential to become the
monotherapy of choice for the treatment of lower urinary tract
symptoms (LUTS) and could target a significant portion of both, the
OAB and BPH markets. We all wish Enrico well in his future
endeavors."

Enrico Colli added "Being with BioXell has, from its very beginning
until today, been very exciting. We made and are making substantial
progress in the clinical development of BioXell's programs addressing
unmet medical needs. While leaving the Company, I am proud of these
accomplishments and I strongly believe that BioXell is on the right
track to successfully complete development of its drug candidates."

About BioXell

BioXell (SWX: BXLN) is a biopharmaceutical company focused on the
discovery and development of drugs that exploit novel mechanisms of
action to treat important urological, inflammatory, and related
disorders with significant unmet medical needs. The Company was
founded in 2002 as a spin-out from Roche. BioXell's strategic goal is
to become a fully integrated pharmaceutical company by maximizing the
commercial potential of its product portfolio and leveraging existing
platforms into profitable partnerships.

BioXell's lead compound, Elocalcitol, derived from its proprietary
VD3 (Vitamin D3) technology platform, has successfully completed a
Phase IIb clinical trial for Benign Prostatic Hyperplasia (BPH).
Elocalcitol is currently in a Phase IIb clinical trial for Overactive
Bladder (OAB) and in a Phase II trial for male infertility. In
addition, the Company has several follow-on programs based on both
VD3 and other technological platforms. These include BXL746, to enter
Phase I/II trials for post-surgical adhesions in early 2009; MNAC13,
an innovative approach to the treatment of pain; and the TREM
platform, with TREM-1 in development for the treatment of
inflammatory conditions.

In June 2006, BioXell listed its shares on the main segment of the
SWX Swiss Exchange. BioXell currently employs 58 people and has sites
in Milan, Italy and Nutley, NJ, USA.

More information on BioXell can be found at: www.bioxell.com

For further information, please contact:

BioXell S.p.A. Dynamics Group SA
Alvise Sagramoso Christophe Lamps
Tel: +39 (0)2 210 49 51 Tel: +41 (0)22 308 6222
Fax: +39 (0)2 210 49 529 Fax: +41 (0)22 308 6236
alvise.sagramoso@bioxell.com cla@dynamicsgroup.ch

This press release can be downloaded at www.bioxell.com.

Disclaimer
This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.

--- End of Message ---

bioXell S.p.A
via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SWX Swiss Exchange;
Copyright © Hugin AS 2008. All rights reserved.